Both corticotropin-releasing factor and apomorphine reduce prepulse inhibition following repeated central infusion of corticotropin-releasing factor

Pharmacology Biochemistry and Behavior

Volumn 85, Issue 1, 2006, Pages 261-272

  Conti, Lisa H ^a   Berridge, Craig W ^b   Tayler, Jane E ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Apomorphine; Brown Norway rats; CRF; Methylphenidate; Prepulse inhibition; Sensorimotor gating; Startle

Indexed keywords

APOMORPHINE; CORTICOTROPIN RELEASING FACTOR; METHYLPHENIDATE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; RAT STRAIN; STARTLE REFLEX;

ANIMALS; APOMORPHINE; CORTICOTROPIN-RELEASING HORMONE; MALE; RATS;

RATTUS NORVEGICUS; RODENTIA;

EID: 33751075476     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.08.009     Document Type: Article

References (51)

1. Bakshi V.P., and Geyer M.A. Alpha-1-arenergic receptors mediate sensorimotor gating deficits produced by dizocilpine administration in rats. Neuroscience 92 (1999) 113-121
2. Bakshi V.P., Alsene K.M., and Connors E.E. Acute and long-term effects of stress and CRF on prepulse inhibition. Neuropsychopharmacology 30 Suppl 1 (2004) S45
3. Bale T.L., and Vale W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44 (2004) 525-557
4. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AFT, Kelley AE, Schmeichel B, Hamilton C, Spencer RC. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry, in press.
5. Braff D., Stone C., Callaway E., Geyer M., Glick I., and Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15 (1978) 339-343
6. Buwalda B., Van Kalkeren A.A., de Boer S.F., and Koolhaas J.M. Behavioral and physiological consequences of repeated daily intracerebroventricular injection of corticotropin-releasing factor in the rat. Psychoneuroendocrinology 23 (1998) 204-218
7. Cador M., Cole B.J., Koob G.F., Stinus L., and Le Moal M. Central administration of corticotropin releasing factor induces long-term sensitization to d-amphetamine. Brain Res 606 (1993) 181-186
8. 1 receptor mRNA expression. J Neurosci 15 (1995) 6340-6350
9. Cole B.J., and Koob G.F. Low doses of corticotropin-releasing factor potentiate amphetamine-induced stereotyped behavior. Psychopharmacology 99 (1989) 27-33
10. Conti L.H. Characterization of the effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in Brown Norway and Wistar-Kyoto rats. Eur J Pharmacol 507 (2005) 125-134
11. Conti L.H., and Foote S.L. Effects of pretreatment with corticotropin-releasing factor on the electrophysiological responsivity of the locus coeruleus to subsequent corticotropin-releasing factor challenge. Neuroscience 69 (1995) 209-219
12. Conti L.H., Murry J.D., Ruiz M.A., and Printz M.P. Effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in two rats strains. Psychopharmacology 161 (2002) 296-303
13. Conti L.H., Costill J.E., Flynn S., and Tayler J.E. Effects of a typical and an atypical antipsychotic on the disruption of prepulse inhibition caused by corticotropin-releasing factor and rat strain. Behav Neurosci 119 (2005) 1052-1060
14. Culm K.E., Lugo-Escobar N., Hope B.T., and Hammer R.P. Repeated quinpirole treatment increases cAMP-dependent protein kinase activity and CREB phosphorylation in nucleus accumbens and reverses quinpirole-induced sensorimotor gating deficits in rats. Neuropsychopharmacology 29 (2004) 1823-1830
15. Davis M. Apomorphine, d-amphetamine, strychnine and yohimbine do not alter prepulse inhibition of the acoustic startle reflex. Psychopharmacology 95 (1988) 151-156
16. De Souza E.B. Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J Neurosci 7 (1987) 88-100
17. Dirks A., Groenink L., Schipholt M.I., van der Gugten J., Hijzen T.H., Geyer M.A., et al. Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry 51 (2002) 583-590
18. Dirks A., Groenink L., Westphal K.G., Oliver J.D., Verdouw P.M., van der Gugten J., et al. Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs. Neuropsychopharmacology 28 (2003) 1790-1798
19. Drolet G., Proulx K., Pearson D., Rochford J., and Deschepper C.F. Comparisons of behavioral and neurochemical characteristics between WKY, WKHA, and Wistar rat strains. Neuropsychopharmacology 27 (2002) 400-409
20. Druhan J.P., Geyer M.A., and Valentino R.J. Lack of sensitization to the effects of d-amphetamine and apomorphine on sensorimotor gating in rats. Psychopharmacology 135 (1998) 296-304
21. Feifel D., Reza T.L., Wustrow D.J., and Davis M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exper Ther 288 (1999) 710-713
22. Gabr R., Gladfelter W.E., Birkle D.L., and Azzaro A.J. In vivo microdialysis of corticotropin releasing factor (CRF): calcium dependence of depolarization-induced neurosecretion of CRF. Neurosci Lett 169 (1991) 63-67
23. Geyer M.A., Swerdlow N.R., Mansbach R.S., and Braff D.L. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25 (1990) 625-648
24. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156 (2001) 117-154
25. Hammer R.P., and Arrillaga-Romany I.C. Is dopamine to blame for CRF-induced sensorimotor gating deficits in rats?. Neuropsychopharmacology 30 Suppl 1 (2004) S44
26. Hammond G.R., Macadam D.W., and Ison J.R. Effects of prestimulation on the electromyographic response associated with the acoustic startle reaction in rats. Physiol Behav 8 (1972) 535-537
27. Izzo E., Sanna P.P., and Koob G.F. Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor. Pharmacol Biochem Behav 81 (2005) 701-708
28. Kalivas P.W., Duffy P., and Latimer L.G. Neurochemical and behavioral effects of corticotropin-releasing factor in the ventral tegmental area of the rat. J Pharmacol Exp Ther 242 (1987) 757-763
29. Kuczenski R., and Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68 (1997) 2032-2037
30. Lavicky J., and Dunn A.J. Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis. J Neurochem 60 (1993) 602-612
31. Liang K.C., Melia K.R., Miserendino M.J., Falls W.A., Campeau S., and Davis M. Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J Neurosci 12 (1992) 2303-2312
32. Mackeprang T., Kristiansen K.T., and Glenthoj B.Y. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenia patients. Biol Psychiatry 52 (2002) 863-873
33. Mansbach R.S., Geyer M.A., and Braff D.L. Dopaminergic stimulation disrupts sensori motor gating in the rat. Psychopharmacology 94 (1988) 507-514
34. Martin-Iverson M.T. Does sensitization occur to prepulse inhibition of the startle reflex effects of repeated apomorphine treatments in rats?. J Pharmacol 13 (1999) 261-273
35. Matsuzaki I., Takamatsu Y., and Moroji T. The effects of intracerebroventricularly injected corticotropin-releasing factor (CRF) on the central nervous system: behavioral and biochemical studies. Neuropeptides 13 (1989) 147-155
36. Meloni E.G., Gerety L.P., Knoll A.T., Cohen B.M., and Carlezon W.A. Behavioral and anatomical interactions between dopamine and corticotropin-releasing factor in the rat. J Neurosci 26 (2006) 3855-3863
37. Parwani A., Duncan E.J., Bartlett E., Madonick S.H., Efferen T.R., Rajan R., et al. Impaired prepulse inhibition of acoustic startle in schizophrenia. Biol Psychiatry 47 (2000) 662-669
38. Radulovic J., Sydow S., and Spiess J. Characterization of native corticotropin-releasing factor receptor type 1 (CRFR1) in the rat and mouse central nervous system. J Neurosci Res 54 (1998) 507-521
39. Rigdon G.C. Differential effects of apomorphine on prepulse inhibition of acoustic startle reflex in two rat strains. Psychopharmacology 102 (1990) 419-421
40. Risbrough V.B., Hauger R.L., Pelleymounter M.A., and Geyer M.A. Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology 170 (2003) 178-187
41. 2 exert both additive and opposing influences on startle defensive behavior. J Neurosci 24 (2004) 6545-6552
42. Rivier C., and Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 305 (1983) 325-333
43. Song C., Earley B., and Leonard B.E. Behavioral, neurochemical, and immunological responses to CRF administration. Is CRF a mediator of stress?. Ann NY Acad Sci 771 (1995) 55-72
44. Swerdlow N.R., Britton K.T., and Koob G.F. Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and fear are both reversed by alpha-helical CRF (9-41). Neuropsychopharmacology 2 (1989) 285-292
45. Swerdlow N.R., Braff D.L., Taaid N., and Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51 (1994) 139-154
46. Swerdlow N.R., Platten A., Kim Y.K., Gaudet I., Shoemaker J., Pitcher L., et al. Sensitivity to the dopaminergic regulation of prepulse inhibition in rats: Evidence for genetic, but not environmental determinants. Pharmacol Biochem Behav 70 (2001) 219-226
47. Swerdlow N.R., Stephany N., Wasserman L.C., Talledo J., Shoemaker J., and Auerbach P.P. Amphetamine effects on prepulse inhibition across-species: replication and parametric extension. Neuropsychopharmacology 28 (2003) 640-650
48. Swerdlow N.R., Shoemaker J.M., Platten A., Pitcher L., Goins J., and Crain S. Heritable differences in the effects of amphetamine but not DOI on startle gating in albino and hooded outbred rats. Pharmacol Biochem Behav 75 (2003) 181-197
49. Swerdlow N.R., Shoemaker J.M., Aurbach P.P., Pitcher L., Goins J., and Platten A. Heritable differences in dopaminergic regulation of sensorimotor gating: II. Temporal, pharmacologic and generational analyses of apomorphine effects on prepulse inhibition. Psychopharmacology 174 (2004) 452-462
50. Swerdlow N.R., Kuczenski R., Goins J.C., Crain S.K., Ma L.T., Bongiovanni M.J., et al. Neurochemical analysis of rat strain differences in the startle gating-disruptive effects of dopamine agonists. Pharmacol Biochem Behav 80 (2005) 203-211
51. Van Bockstaele E.J., Colago E.E., and Valentino R.J. Amygdaloid corticotropin-releasing factor targets locus coeruleus dendrites: substrate for the co-ordination of emotional and cognitive limbs of the stress response. J Neuroendocrinology 10 (1998) 743-757